Clinical trial · Observational
Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The use of an ultrathin bronchoscope (UB) has recently been introduced in the diagnosis of peripheral lung lesions. The use of the UB can be supported by navigation systems such as fluoroscopy, ultrasound guidance, electromagnetic navigation, or other technologies, which have complementary potential. Further navigation techniques are still under study. The use of ultrathin instrumentation has already been shown to significantly reduce procedural times compared to traditional instrumentation. The purpose of the study is to prospectively evaluate the institutional experience of different third-level hospital centers with the use of a UB (MP190F; Olympus Medical Systems, Tokyo, Japan) for sampling peripheral lung lesions by means of transbronchial needle aspiration (TBNA) or transbronchial biopsy (TBB), performed after fluoroscopic navigation and simultaneous radial probe-endobronchial ultrasound (RP-EBUS) assessment. Design: multicentric, observational study.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Diseases | — | UNRESOLVED | — |
| Lung; Node | — | UNRESOLVED | — |
| Lung TB | — | UNRESOLVED | — |
| Lung Transplant Rejection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluate the overall diagnostic accuracy
- timeFrame
- Within 12 months from the procedure
- description
- Sensitivity, specificity, positive predictive value, negative predictive value
Secondary outcomes (4)
- measure
- Agreement between the definitive pathological result and the rapid on-site evaluation (R.O.S.E.)
- timeFrame
- Within 15 days from the procedure
- description
- Comparison (% of concordant and % of discordant results) between R.O.S.E. (performed during the procedure by the pulmonologist or by the pathologist) and the final result obtained after the evaluation (by the pathologist) of the samples taken.
- measure
- Evaluation of patient satisfaction at the end of the procedure (Likert scale in relation to the memory of the procedure and the willingness to repeat it in the future.)
- timeFrame
- Same day of the procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Candidate for a diagnostic procedure for a new peripheral lung lesion or re-biopsy; * Tissue sampling of the peripheral lesion performed only with UB; * The patient's ability to understand the individual characteristics and consequences of the clinical study; * Males and females of any ethnicity; * Subjects who have given their informed consent to use their clinical data for research purposes. Exclusion criteria: * Inability to give informed consent or understand its contents; * Unavailability of tomographic imaging; * Failure to use RP-EBUS or fluoroscopic guidance during the procedure; * Failure to use R.O.S.E. by the pulmonologist or pathologist during the procedure; * Tissue sampling on the same peripheral lesion using an instrument of a different caliber in replacement or in association; * Any other significant illness or disorder that, in the investigator's opinion, may put the patient at risk due to study participation.
References
Publications (0)
Data not yet available